|Source: Erin Silversmith, Wikimedia|
Read more about how VEGF-A inhibitors treat macular degeneration.
One such VEGF-A antagonist is Lucentis, and it is the only available treatment that has been shown to potentially restore vision. It halted the progression of blindness in 95 percent of patients in clinical trials, and improved vision in 40 percent. The drug contains an antibody fragment that binds VEGF-A to prevent it from acting on its receptor. The solution is injected directly into the eye. Read about Lucentis (ranibizumab injection).